AlphaCore Aiming High with Recombinant LCAT
By Marie Powers
Staff Writer
Staff Writer
Wednesday, January 2, 2013
AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, befitting a biotech working in the rare orphan indication of familial LCAT deficiency. The inherited condition causes corneal opacities, anemia and renal disease due to the accumulation of LCAT substrates (unesterified cholesterol and phospholipid).
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.